Highnoon Laboratories Limited (PSX: HINOON)

Market Cap	46.61B
Revenue (ttm)	23.02B
Net Income (ttm)	3.02B
Shares Out	52.98M
EPS (ttm)	56.98
PE Ratio	15.44
Forward PE	n/a
Dividend	30.00 (3.33%)
Ex-Dividend Date	Apr 18, 2024

Volume	22,757
Average Volume	12,771
Open	912.00
Previous Close	899.67
Day's Range	875.00 - 912.00
52-Week Range	465.50 - 1,000.00
Beta	0.20
RSI	40.65
Earnings Date	Mar 7, 2025

About Highnoon Laboratories

Highnoon Laboratories Limited, together with its subsidiaries, manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. It offers products in various therapeutic areas, including allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynaecology, paediatrics, respiratory, and urology; and generic products under various brands. The company serves Pakistan, Afghanistan, the United Arab Emirates, France, Kenya, Iraq, Cambodia, Tanzania, and internationally. Highnoon ...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1984
• Employees: 2,295
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HINOON

Financial Performance

In 2023, Highnoon Laboratories's revenue was 19.77 billion, an increase of 24.98% compared to the previous year's 15.82 billion. Earnings were 2.45 billion, a decrease of -1.01%.